Home / Pharmaceutical / The Pharmaceutical Market: Oman

The Pharmaceutical Market: Oman

Published: Dec 2014 | No Of Pages: 102 | Published By: Espicom

Product Synopsis

Oman Pharmaceuticals & Healthcare Report
 
Oman's commendable public healthcare system and high-class tertiary and quaternary care hospitals will increase the uptake of medical tourism by GCC citizens. The Omani pharmaceutical market will continue to remain heavily reliant on imports due to the costly need to source raw ingredients for local manufacturing and lack of R&D backing. However, despite t he strict drug pricing system, we are likely to see more multinational companies penetrating the market and expanding volume sales, by addressing the increasing burden of non-communicable diseases in the country.
 
Headline Expenditure Projections
  • Pharmaceuticals: OMR151mn (US$391mn) in 2011 to OMR166mn in 2012; +9.9% in local currency terms and +11.3% in US dollar terms. Forecastrevised upwards due tomodifications to historical figures.
  • Healthcare: OMR742mn (US$1.93bn) in 2011 to OMR839mn (US$2.21bn) in 2012; +13.1% in local currency terms and +14.6% in US dollar terms. Forecastrevised upwards due tomodifications to historical figures.
  • Medicaldevices: OMR40mn (US$105mn) in 2011 to OMR44mn (US$116mn) in 2012; +9.5% in local currency terms and +10.9% in US dollar terms. Forecastrevised upwards due tomodifications to historical figures.
  • Risk/RewardRating
  • Risk-Reward Rating scores represent a country's pharmaceutical market attractiveness for investment, which includes weightings of risk and rewards analysis of the wider macroeconomic environment. Oman's consistent score of 50.2 out of 100 over the past three quarters places it above the MEA regional average of 44.2, indicating a favourable and stable environment for multinational investment. Oman also currently maintains its position as ninth out of 30 countries in the MEA matrix.
Competitive Landscape
 
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
BMI Industry View7
SWOT10
Political12
Economic13
Business Environment14
Industry Forecast15
Pharmaceutical Market Forecast15
 
Table: Pharmaceutical Sales, Historical Data And Forecasts (Oman 2010-2018)16
 
Healthcare Market Forecast17
 
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2010-2018)18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2010-2018)18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2010-2018)19
 
Prescription Drug Market Forecast20
 
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Oman 2010-2018)21
 
Patented Drug Market Forecast22
 
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Oman 2010-2018)22
 
Generic Drug Market Forecast23
 
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Oman 2010-2018)24
 
OTC Medicine Market Forecast25
 
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Oman 2010-2018)26
 
Pharmaceutical Trade Forecast27
 
Table: Pharmaceutical Trade Data And Forecasts (Oman 2012-2018)28
Table: Pharmaceutical Trade Data And Forecasts local currency (Oman 2012-2018)28
 
Other Healthcare Data29
Key Risks To BMI's Forecast Scenario30
Macroeconomic Forecasts31
Economic Analysis31
 
Table: Economic Activity (Oman 2009-2018)38
 
Industry Risk Reward Ratings39
Middle East & Africa Risk/Reward Index39
Oman Risk/Reward Ratings46
Rewards46
Risks47
Market Overview48
Industry Trends And Developments49
Industry Trends And Developments49
Epidemiology49
Communicable Diseases49
Non-Communicable Diseases50
Healthcare Sector51
Public Healthcare Sector Developments54
Private Healthcare Sector Developments56
 
Table: Number Of Health Centres In Oman By Region58
Table: Number And Type Of Health Institutions In Oman In 201259
 
Healthcare Insurance59
Telemedicine61
Medical Tourism61
Research And Development63
Clinical Trials64
Regulatory Development66
Regulatory Developments67
Intellectual Property Regime67
Regional Harmonisation68
Pricing And Reimbursement Regime69
Competitive Landscape73
Domestic Pharmaceutical Industry73
Foreign Pharmaceutical Industry74
Pharmaceutical Distribution75
Company Profile76
Zynova/Oman Pharmaceutical Products Company76
National Pharmaceutical Industries (NPI)79
Novartis82
GlaxoSmithKline85
Sanofi86
Johnson & Johnson88
Demographic Forecast90
 
Table: Oman's Population By Age Group, 1990-2020 ('000)91
Table: Oman's Population By Age Group, 1990-2020 (% of total)92
Table: Oman's Key Population Ratios, 1990-202093
Table: Oman's Rural And Urban Population, 1990-202093
 
Glossary94
Methodology96
Pharmaceutical Expenditure Forecast Model96
Healthcare Expenditure Forecast Model96
Notes On Methodology97
Risk/Reward Ratings Methodology98
Ratings Overview99
 
Table: Pharmaceutical Risk/Reward Ratings Indicators99
 
Indicator Weightings100
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +